Screener
BioCryst Pharmaceuticals BCRX Contract termination costs
Contract termination costs at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:LossOnContractTermination.
The source filing: BioCryst Pharmaceuticals’s 10-K, filed February 26, 2026.
- Filed
- Feb 26, 2026, 4:03 PM EST
- Fiscal year
- FY2025
- Accession
- 0001628280-26-012240
During the year ended December 31, 2023, the Company recorded an impairment loss of $1,548 and contract termination fees of $440 related to the discontinuation of the Birmingham research facilities expansion, which was recognized in research and development expenses during the year ended December 31, 2023. The Company did not record any impairment losses during the years ended December 31, 2025 and 2024.
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
FAQ
- What is BioCryst Pharmaceuticals's contract termination costs?
- BioCryst Pharmaceuticals (BCRX) reported contract termination costs of $110K in Q4 2023.
- What does contract termination costs mean?
- Contract termination costs as reported by BioCryst Pharmaceuticals Inc.
Ask your AI about BioCryst Pharmaceuticals's contract termination costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude